Work

IMpactMF, randomized, open-label, phase 3 trial of imetelstat (IME) versus best available therapy (BAT) in patients (pts) with intermediate-2 (INT-2) or high-risk (HR) myelofibrosis (MF) relapsed or refractory (R/R) to Janus kinase inhibitors (JAKi).

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps6588

Authors: John Mascarenhas, Claire Harrison, Prithviraj Bose, Jean-Jacques Kiladjian, Alessandro Lucchesi, Alessandro Vannucchi, Michelle Mudge-Riley, Jennifer Riggs, Lixian Peng, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Chendeal Navada, Rami S. Komrokji

Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, National Health Service, The University of Texas MD Anderson Cancer Center, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, University of Florence, Geron (United States), Moffitt Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410817075

FWCI:

Cites:

Cited by:

Related to: 10